Resolvin E2

Synonyms: (-)-Resolvin E2
Resolvin E2 ((-)-Resolvin E2) 是一种由 5-脂氧酶 (5-LOX) 催化二十碳五烯酸 (EPA) 产生的内源性脂质介质,在缺氧环境中生成量会增加,可拮抗 BLT1、部分激活 ChemR23 并促进泛素-蛋白酶体介导的 COX-2 降解,从而减少前列腺素 E2 的生成、阻断多形核白细胞浸润、促进气道炎症消退,并改善由脂多糖 (LPS) (MS-X54539) 诱导的抑郁样行为,可用于抑郁症、小鼠腹膜炎及新生儿哮喘等相关研究。
产品编号: MS-W08086 纯度: 98.5% CAS No.: 865532-70-3 分子式: C20H30O4 分子量: 334.45
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5μg (149.50μM * 100μL in Ethanol)
询价
3-5 天

产品描述

Resolvin E2 ((-)-Resolvin E2) 是一种由 5-脂氧酶 (5-LOX) 催化二十碳五烯酸 (EPA) 产生的内源性脂质介质,在缺氧环境中生成量会增加,可拮抗 BLT1、部分激活 ChemR23 并促进泛素-蛋白酶体介导的 COX-2 降解,从而减少前列腺素 E2 的生成、阻断多形核白细胞浸润、促进气道炎症消退,并改善由脂多糖 (LPS) (MS-X54539) 诱导的抑郁样行为,可用于抑郁症、小鼠腹膜炎及新生儿哮喘等相关研究。

生物实验数据

生物活性 Resolvin E2 ((-)-Resolvin E2) is an endogenous lipid mediator produced from eicosapentaenoic acid (EPA) via 5-lipoxygenase (5-LOX) catalysis, with increased generation under hypoxic conditions; it antagonizes BLT1, partially activates ChemR23, and promotes ubiquitin-proteasome-mediated COX-2 degradation, thereby reducing prostaglandin E2 production, blocking polymorphonuclear leukocyte infiltration, promoting the resolution of airway inflammation, and ameliorating lipopolysaccharide (LPS) (MS-X54539)-induced depressive-like behavior, and it can be used in research related to depression, mouse peritonitis, and neonatal asthma.
体外研究
(In Vitro)

Resolvin E2 (10 nM; 2-16 h) 以时间依赖性方式抑制人巨噬细胞样 U937 细胞中 COX-2 蛋白的表达,且不改变 COX-1 的水平。
Resolvin E2 (10 nM; 4-16 h) 可显著降低人巨噬细胞样 U937 细胞中 PGE2 的生成。
Resolvin E2 (10 nM; 8 h) 可通过泛素-蛋白酶体系统促进人巨噬样 U937 细胞中 COX-2 蛋白的降解。

Western Blot Analysis

Cell Line: human macrophage-like U937 cells (differentiated with phorbol 12-myristate 13-acetate)
Concentration: 10 nM
Incubation Time: 2 h, 4 h, 8 h, 16 h
Result: Did not alter COX-1 protein levels at any time point tested.
Suppressed COX-2 protein expression in a time-dependent manner, with statistically significant suppression observed at 4 h, 8 h, and 16 h compared to the 0 h control.

ELISA Assay

Cell Line: human macrophage-like U937 cells (differentiated with phorbol 12-myristate 13-acetate)
Concentration: 10 nM
Incubation Time: 2 h, 4 h, 8 h, 16 h
Result: Reduced PGE2 production in a time-dependent manner, with statistically significant suppression observed at 4 h, 8 h, and 16 h compared to the 0 h control.

Real Time qPCR

Cell Line: human macrophage-like U937 cells (differentiated with phorbol 12-myristate 13-acetate)
Concentration: 10 nM
Incubation Time: 2 h, 4 h, 8 h, 16 h
Result: Did not suppress COX-2 mRNA expression at any time point tested, with no statistically significant differences compared to the 0 h control.

Western Blot Analysis

Cell Line: human macrophage-like U937 cells (differentiated with phorbol 12-myristate 13-acetate)
Concentration: 10 nM (Resolvin E2); 0.3 μM (MG132 pretreatment)
Incubation Time: 8 h (Resolvin E2); 30 min (MG132 pretreatment)
Result: Suppressed COX-2 protein expression when administered alone.
Had its COX-2 protein expression suppression abrogated by pretreatment with 0.3 μM MG132, which restored COX-2 protein levels to a similar level as the untreated control.
体内研究
(In Vivo)

Resolvin E2 (1-10 ng;侧脑室注射;单次输注) 可在 LPS 诱导的小鼠抑郁样行为中呈剂量依赖性地产生抗抑郁作用,在强迫游泳实验中 10 ng 侧脑室注射剂量下观察到显著药效。
Resolvin E2 (1-100 ng;静脉注射、腹腔注射;单次给药) 可强效降低酵母聚糖诱导的小鼠腹膜炎中人类中性粒细胞 (PMN) 的浸润。
Resolvin E2 (300 ng/小鼠;滴鼻给药;每日 1 次;连续 3 天) 可通过降低气道嗜酸性粒细胞增多、肺组织浸润及变应原性细胞因子水平,缓解高风险幼崽的新生儿哮喘。

Animal Model: BALB/c (male, 11-12 weeks old, LPS-induced depression model)
Dosage: 1 ng; 10 ng
Administration: i.c.v.; single infusion
Result: Dose-dependently decreased LPS-induced increases in immobility time in the tail suspension test.
Significantly suppressed LPS-induced increases in immobility time in the forced swim test at the 10 ng i.c.v. dose.
Had no effect on immobility time in saline-injected control mice in either tail suspension or forced swim tests.
Did not affect locomotor activity or anxiety-like behavior (time spent in the center of an open field chamber) in either LPS-challenged or saline-injected mice.
Animal Model: FVB (male, 6-8 weeks old, peritonitis induced by intraperitoneal injection of 1 mg zymosan A in 1 mL saline)
Dosage: 1 ng (i.v., side-by-side comparison); 10 ng (i.v., side-by-side comparison); 100 ng (i.v., side-by-side comparison); 10 ng (i.v., route comparison); 10 ng (i.p.)
Administration: i.v.; single dose; i.p.; single dose
Result: Reduced PMN infiltration by 11.3% compared to controls.
Reduced PMN infiltration by 17.7% compared to controls.
Reduced PMN infiltration by 33.7% compared to controls.
Reduced PMN infiltration by 47.6% compared to controls.
Reduced PMN infiltration by 34.5% compared to controls.
Combined with 10 ng Resolvin E1 (i.v.) reduced PMN infiltration additively.
Showed potency not significantly different from Resolvin E1 at any tested dose.
Animal Model: BALB/c (neonatal, offspring of time-pregnant E13 BALB/c dams; neonatal asthma model induced by maternal gestational exposure to CAPs/DEPs (concentrated urban air particles and diesel exhaust particles) at E14-E20, followed by neonatal OVA (MS-Q48215) sensitization and challenge)
Dosage: 300 ng/mouse
Administration: i.n.; once daily; 3 days
Result: Reduced BAL eosinophil counts by more than half and eosinophil percentages by ~20% in offspring of CAP- or DEP-exposed dams compared to untreated at-risk pups.
Decreased BAL IL-5 levels in offspring of DEP-exposed dams.
Decreased BAL IL-13 levels in offspring of DEP-exposed dams.
Decreased serum IL-5 levels in offspring of CAP-exposed dams.
Ameliorated lung tissue inflammatory infiltration compared to untreated at-risk pups.
Showed no effect in offspring of PBS-exposed control dams.
性状 液体
颜色 Colorless to light yellow

化学信息

分子量 334.45
分子式 C20H30O4
CAS No. 865532-70-3
别名 (-)-Resolvin E2

储存&溶解度

溶解度信息
Ethanol: 1 mg/mL (2.99 mM), Sonication is recommended.
储存方式

Solution, -20°C, 2 years

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础